Skip to main content

Table 2 Demographic characteristics and baseline details of the study participants

From: Posterior segment inflammatory outcomes assessed using fluorescein angiography in the STOP-UVEITIS study

Study group Group 1 (4 mg/kg) n = 18 Group 2 (8 mg/kg)
n = 19
P-value
Gender [% female (n)] 61.1 (11) 57.9 (11) 1.0
Race [% white (n)] 88.9 (16) 79.0 (15) 0.11
Race [%Asian (n)] 0.0 (0) 10.5 (2)
Race [% Hispanic or Latin (n)] 11.1 (2) 0.0 (0)
Race [% African American (n)] 0.0 (0) 10.5 (2)
Age (mean years ± SD) 43 ± 16.52 (18 – 68) 41 ± 18.0 (19 – 85) 0.79
Visual acuity (mean ± SD) 34.28 ± 15.39 41.11 ± 14.98 0.18
Vitreous haze (mean ± SD) 1.25 ± 0.82 1.5 ± 0.95 0.48
Central macular thickness (mean ± SD) 411.97 ± 215.43 308.76 ± 91.03 0.08
Lens status (% pseudophakic) 27.8 (5) 15.8 (3) 0.45
Treatment Naïve (%) 55.5 (10) 63.1 (12) 0.74
Systemic corticosteroid use (%(n)) 27.8 (5) 21.1 (3) 0.45
Corticosteroid dose (mean ± SD) 18.0 ± 12.5 20.0 ± 14.1 0.86
Prior IMT use (%(n)) 22.2 (4) 26.3 (5) 1.0
Disease Type [% (n)]    
Intermediate 16.7 (3) 15.8 (3) 0.30
Posterior 22.2 (4) 5.3 (1)
Panuveitis 61.1 (11) 78.9 (15)
Disease category [% (n)]
 Active uveitis with no treatment 55.6 (10) 68.4 (13) 0.51
 Active uveitis with treatment 44.4 (8) 31.6 (6)
Underlying disease [% (n)]
 Sarcoidosis 5.6 (1) 5.3 (1) 0.27
 Vogt-Koyangi-Harada Syndrome   10.5 (2)
 Birdshot choroidopathy 11.1 (2)  
 Punctate inner choroiditis 5.6 (1)  
 Bechet disease 5.6 (1)  
 Tubulointerstitial nephritis and uveitis (TINU syndrome) 5.6 (1)  
 Idiopathic 66.7 (12) 84.2 (16)